Colleen M Scott, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 22905 W Main St, Armada, MI 48005 Phone: 586-473-8082 Fax: 586-473-8129 |
News Archive
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (VelcadeĀ®).
In a feature story, Al Jazeera examines Cuba's national health care system, which "works - or is supposed to work - by emphasizing primary and preventative health care." However, after subsidies from the former Soviet Union "ended and Cuba's economy went into a tailspin, nothing was the same again," according to the news agency, which notes the system experiences drug shortages, patients have long wait times, and some hospitals are dirty or malfunctioning.
Six states have taken this position, according to the Texas Tribune. Meanwhile, media outlets report on new developments regarding state activity on the health law's Medicaid expansion and health exchanges.
Cancer prevention experts have long been frustrated by the lack of a meaningful way to screen women for ovarian cancer. It is a relatively rare disease that often progresses with few symptoms until it is too late for potentially curative treatments, and elevated values of the most commonly used biomarker used in screening, CA125, are also related to other disorders.
› Verified 8 days ago